Clinical Trial Update: Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of rogaratinib (pan-FGFR inhibitor) in neoplasms completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Rogaratinib

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2020-04-28